View Press Releases
Thomson Reuters and Linguamatics Release New Solution to Advance Pharma Clinical Trial R&D
PHILADELPHIA, PA - Dec 4, 2014 - The Intellectual Property & Science business of Thomson Reuters, the world leader in intelligent information for businesses and professionals, today announced a collaboration with Linguamatics to advance pharmaceutical clinical trial research and development (R&D) with the launch of CortellisTM Informatics Clinical Text Analytics for I2E. The new solution, available through Thomson Reuters Cortellis-the most powerful intelligence platform for life science professionals-applies Linguamatics I2E text mining platform to relevant information to assist researchers in finding actionable insights. The content includes clinical trial information, epidemiology data, literature, press releases and conference proceedings.
Cortellis Informatics Clinical Text Analytics for I2E uses the combination of Linguamatics powerful, market-leading NLP text analytics platform with the largest breadth and depth of integrated clinical content available. Through a single interface, users will be able to glean new insights in support of trials, site selection and competitive intelligence, helping them to design more effective clinical trials and gain a deeper understanding of the implications of their results.
We are excited about this innovative project with Thomson Reuters said John Brimacombe, executive chairman of Linguamatics. Combining the strength of our best of breed text analytics with the wealth of content within Cortellis will be a significant step forward for our clients in advancing productivity and efficacy in pharmaceutical R&D.
Key features include:
- Authoritative, Hand-Curated Content: Users
will be able to gain greater insights from their data with the
combination of state-of-the-art text and high quality, hand curated
content offered by Cortellis Informatics Clinical Text Analytics
for I2E.
- Access to Numeric Information: Advanced Text
Analytics will allow for rapid extraction and connection of
relevant facts and relationships within the content, improving
speed to insight.
- Data-Driven Clinical Insights: The ability to
generate data tables from these resources will support users in
preclinical studies, trial design, business intelligence, and
provide a deeper understanding of the impact of clinical
trials.
- Streamlines Search Functionality: Fast,
easy-to-use functionality allows for timely and accurate
searches.
We are pleased to be working with Linguamatics to provide the pharmaceutical industry with a solution that leverages the leading capabilities of both organizations and will provide our mutual customers with a stronger view into the clinical trial process, said Jon Brett-Harris, managing director of Thomson Reuters Life Science business. Our joint solution will make it easier for researchers to obtain the insights they need to help them make decisions that optimize the drug development process.
Learn more about
Cortellis Informatics Clinical Text Analytics for I2E and Cortellis
About Linguamatics
Linguamatics is the world leader in deploying innovative natural
language processing (NLP)-based text mining for high-value
knowledge discovery and decision support. Linguamatics I2E is used
by top commercial, academic and government organizations, including
17 of the top 20 global pharmaceutical companies, the US Food and
Drug Administration (FDA) and leading US healthcare providers. I2E
can be used to mine a wide variety of text resources, such as
scientific literature, patents, Electronic Health Records (EHRs),
clinical trials data, news feeds, social media and proprietary
content. I2E can be deployed as an in-house enterprise system, an
add-on to enterprise search, or as Software-as-a-Service (SaaS) on
the cloud.
Linguamatics is a winner of the Queens Award for Enterprise 2014
for International Trade. www.linguamatics.com
About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. For more information, go to www.thomsonreuters.com.